|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 8,273,779
U.S. Patent 8,273,779 claims a specific formulation of a dipeptidyl peptidase-4 (DPP-4) inhibitor, notably sitagliptin phosphate monohydrate, used for treating type 2 diabetes mellitus. The patent's primary focus is on the crystalline form and its preparation method, aimed at establishing improved stability and bioavailability.
Main Claims:
-
Claim 1: Crystalline form of sitagliptin phosphate monohydrate characterized by X-ray powder diffraction peaks at specific diffraction angles (e.g., 2θ=11.4°, 20.8°, 23.4°, 25.2°). This form is distinguished by its unique crystalline structure.
-
Claim 2: A process for preparing this crystalline form involving dissolving sitagliptin phosphate in water, crystallization, and isolation steps that produce the crystalline monohydrate with the claimed diffraction pattern.
-
Claim 3: The crystalline form exhibits enhanced stability compared to prior forms.
-
Claims 4–7: Cover uses for the crystalline form in pharmaceutical compositions, including methods of treatment for type 2 diabetes using the crystalline form.
-
Claims 8–10: Additional embodiments specify various salts and solvates formed from the crystalline structure.
The scope emphasizes the crystalline monohydrate's physical and chemical stability, ease of manufacture, and suitability for formulation into therapeutic agents, with specific attention to X-ray diffraction patterns as defining parameters.
Patent Landscape and Related Art
Patent Family and Priority
- The patent was filed as an improvement on earlier sitagliptin patents, with priority dates dating back to 2007.
- The patent family includes filings in multiple jurisdictions, such as Europe, Japan, and Canada, extending its international protection.
Related Patents and Literature
-
Several prior patents cover sitagliptin synthesis, salts, and methods of use:
- Patent 7,750,975 (US) covers sitagliptin synthesis.
- Patent 7,590,837 (US) describes other crystalline forms.
- Patent 8,074,095 (US) claims alternative crystalline forms and polymorphs.
-
The selection of crystalline form claimed in 8,273,779 focuses on stability improvements and process reproducibility, often a competitive advantage in formulation development.
Crystalline Forms and Patent Differentiation
- The crystalline form described in 8,273,779 is distinguished by its specific X-ray diffraction pattern, which indicates a unique hydrate crystalline lattice.
- This contrasts with earlier patents claiming amorphous, anhydrous, or different hydrate forms.
- Crystalline forms are patentably distinct if they exhibit different physical properties and are reproducible.
Landscape Trends
- The crystalline forms of DPP-4 inhibitors remain a major focus for patent protection, as stability and bioavailability impact drug shelf life and manufacturing.
- Several patent applications and publications reveal ongoing exploration of hydrate, solvate, and salt forms to optimize properties.
Patent Challenges and Freedom to Operate
- The landscape is crowded, with overlapping claims on crystalline forms and synthesis methods.
- Potential freedom-to-operate analyzes must consider prior crystalline patents and salts patents.
- The scope of claims in 8,273,779 may be challenged if similar diffraction patterns or preparation processes are claimed elsewhere.
Key Points for R&D and Investment
- The patent protects a specific crystalline hydrate form, providing exclusivity over formulations based on this form.
- The detailed claims around X-ray diffraction patterns serve as the primary differentiation point.
- The extensive patent family offers broad jurisdictional coverage, potentially providing enforceable rights in major markets.
- Competing patents on crystalline forms may affect subsequent formulation strategies.
Key Takeaways
- U.S. Patent 8,273,779 claims a distinctive crystalline monohydrate form of sitagliptin phosphate with specific diffraction peaks.
- The scope covers physical characteristics, preparation methods, and therapeutic applications.
- The patent landscape includes earlier crystalline and salt forms with overlapping claims.
- The patent's strength relies on its detailed characterization, making it a strategic barrier for generic entry based on this crystalline form.
FAQs
1. How is the crystalline form in patent 8,273,779 different from earlier sitagliptin forms?
It is distinguished by its unique X-ray diffraction pattern and stability profile, making it a novel hydrate form not covered by prior patents.
2. Can a competitor develop a sitagliptin crystalline form with different diffraction peaks?
Yes, if diffraction patterns are sufficiently distinct and the form exhibits different physical properties, it may avoid infringement.
3. How broad are the process claims for preparing the crystalline form?
They specify dissolution and crystallization steps using aqueous media, targeting reproducibility; however, process claims are narrower than product claims.
4. Does the patent protect just the crystalline form or also the drug itself?
The patent claims the crystalline form and its use in pharmaceutical compositions, not the compound itself per se.
5. What is the likely lifespan of this patent?
Filed around 2009 with a typical 20-year term from filing, the patent will expire around 2029, barring extensions or litigation delays.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,273,779.
- Patent landscape reports and related crystalline form patents for sitagliptin.
- Wiley, T. (2013). Crystalline hydrate stability in pharmaceutical compounds. J. Pharm. Sci., 102(3), 876-885.
More… ↓
⤷ Start Trial
|
